Unknown

Dataset Information

0

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.


ABSTRACT: The AKT/mammalian target of rapamycin (AKT/mTOR) and ERK MAPK signaling pathways have been shown to cooperate in prostate cancer progression and the transition to androgen-independent disease. We have now tested the effects of combinatorial inhibition of these pathways on prostate tumorigenicity by performing preclinical studies using a genetically engineered mouse model of prostate cancer. We report here that combination therapy using rapamycin, an inhibitor of mTOR, and PD0325901, an inhibitor of MAPK kinase 1 (MEK; the kinase directly upstream of ERK), inhibited cell growth in cultured prostate cancer cell lines and tumor growth particularly for androgen-independent prostate tumors in the mouse model. We further showed that such inhibition leads to inhibition of proliferation and upregulated expression of the apoptotic regulator Bcl-2-interacting mediator of cell death (Bim). Furthermore, analyses of human prostate cancer tissue microarrays demonstrated that AKT/mTOR and ERK MAPK signaling pathways are often coordinately deregulated during prostate cancer progression in humans. We therefore propose that combination therapy targeting AKT/mTOR and ERK MAPK signaling pathways may be an effective treatment for patients with advanced prostate cancer, in particular those with hormone-refractory disease.

SUBMITTER: Kinkade CW 

PROVIDER: S-EPMC2518074 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3631141 | biostudies-literature
| S-EPMC3031409 | biostudies-literature
| S-EPMC5431878 | biostudies-literature
| S-EPMC7572750 | biostudies-literature
| S-EPMC9449649 | biostudies-literature
2012-07-03 | E-GEOD-39054 | biostudies-arrayexpress
| S-EPMC7416412 | biostudies-literature
| S-EPMC3432676 | biostudies-literature
| S-EPMC5454997 | biostudies-literature
| S-EPMC7281543 | biostudies-literature